The small number of patients who were reintroduced to an anti-EGFR-based regimen at disease progression, particularly in the non-maintenance cohort, limited further assessment of the value of a “stop-and-go” strategy, which might be effective in patients with rapid and deep tumor responses, with low tumor burden, especially, but not only, if converted to radical surgery following an anti-EGFR-containing first-line induction, or in those patients who experienced severe or disabling skin toxicity (27). This evidence concerns the gene EGFR and neoplasm.